AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00262795
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
Trial: NCT00310037
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00780793
Drug: progressive spacing of TNF-blocker injections
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop
Trial: NCT01334671
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
Trial: NCT00325325
Drug: everolimus and tacrolimus
RxNorm normalized name: Everolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04360174
Drug: OTX-TIC
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: OTX-TIC implant is injection in the anterior chamber of the eye
Trial: NCT02252432
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
Trial: NCT02252432
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of IV methadone (0.2 mg/kg) preinduction.
Trial: NCT02252432
Drug: Ketamine + methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
Trial: NCT03281122
Drug: BMS-986224
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00560612
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
Trial: NCT02715362
Drug: TAI-GPC3-CART cells
RxNorm normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
Trial: NCT04241458
Drug: BI 703621
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 703621
Trial: NCT04241458
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam
Trial: NCT02889133
Drug: Iron-dextran
RxNorm normalized name: iron-dextran complex
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
Trial: NCT02889133
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salt water IV - 500 mL, one pint normal saline.
Trial: NCT01856530
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid metered-dose nasal spray, 24 IU, administered once
Trial: NCT03995108
Drug: Mavorixafor
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor provided as 100 mg capsules.
Trial: NCT00334529
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00643409
Drug: levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levofloxacin 500 mg capsule by mouth qd x 10 days
Trial: NCT03193112
Drug: Agomelatine 25 MG Oral Tablet
RxNorm normalized name: Agomelatine 25 mg oral tablet
DrugBank: Agomelatine (DB06594)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: We will treat our patients with Agomelatine tablet of 25 mg.
Trial: NCT02726711
Drug: Trimethaphan
RxNorm normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethaphan will be infused (0.5 - 4.0 mg IV)
Trial: NCT00519428
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
Trial: NCT00519428
Drug: bupropion extra long (XL)
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
Trial: NCT00519428
Drug: escitalopram + bupropion
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: same dosing schedule as for monotherapy
Trial: NCT01107808
Drug: Metformin, Vit D and Calcium
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
Trial: NCT01443338
Drug: Triptergium Wilfordii
RxNorm normalized name: Tripterygium wilfordii whole extract
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
Trial: NCT01443338
Drug: Acitretin
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
Trial: NCT01938248
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
Trial: NCT01938248
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 81 mg once daily
Trial: NCT00807079
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00807079
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01229332
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous 24 h administration
Trial: NCT01229332
Drug: Carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous 24 h administration
Trial: NCT01829711
Drug: Moxetumomab pasudotox
RxNorm normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01829711
Drug: IV Bag Protectant for Moxetumomab pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00811902
Drug: Nerispirdine
RxNorm normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral administration
Trial: NCT01210430
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
Trial: NCT03305705
Drug: Iron Carboxymaltose
RxNorm normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intravenous infusion within 20 min
Trial: NCT03305705
Drug: Sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 250 ml within 20 min
Trial: NCT02057484
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00787176
Drug: Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
Trial: NCT00787176
Drug: Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
Trial: NCT02264847
Drug: Human chorionic gonadotrophin
RxNorm normalized name: Human chorionic gonadotrophin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
Trial: NCT01674374
Drug: Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01209065
Drug: Fosamprenavir
RxNorm normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
Trial: NCT01209065
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
Trial: NCT01395108
Drug: Nemonoxacin
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral once daily
Trial: NCT00223626
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the maximum topiramate test dose is 200 mg/d.
Trial: NCT03347916
Drug: Strawberry juice as (placebo)
RxNorm normalized name: strawberry juice
DrugBank: Strawberry (DB10571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received strawberry juice 5 ml volume, one hour before induction.
Trial: NCT03347916
Drug: Gabapentin Oral Solution [Neurontin]
RxNorm normalized name: gabapentin Oral Solution [Neurontin]
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
Trial: NCT02264847
Drug: clomiphene citrate alone
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clomiphene citrate alone without hCG trigger
Trial: NCT05178303
Drug: SB-1121(1)
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
Trial: NCT05178303
Drug: SB-1121(2)
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
Trial: NCT01886001
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
Trial: NCT01886001
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
Trial: NCT01886001
Drug: Pluronic
RxNorm normalized name: Pluronic F68
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
Trial: NCT03215511
Drug: Selitrectinib (BAY2731954)
RxNorm normalized name: entrectinib
DrugBank: Selitrectinib (DB14896)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Selitrectinib is administered as capsules or liquid formulation.
Trial: NCT02009397
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02009397
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01870362
Drug: Probiotic (Inersan)
RxNorm normalized name: Rezyst Probiotic
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02719990
Drug: somavaratan
RxNorm normalized name: Somavaratan
DrugBank: Somavaratan (DB12421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
Trial: NCT01746420
Drug: rhPDGF-BB Injection
RxNorm normalized name: rhPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Trial: NCT01817582
Drug: Lotemax
RxNorm normalized name: Lotemax
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lotemax gel will be administered as per the dose and schedule specified in the arms.
Trial: NCT01817582
Drug: Restasis
RxNorm normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restasis emulsion will be administered as per the dose and schedule specified in the arms.
Trial: NCT00286780
Drug: AT-101
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
Trial: NCT04223635
Drug: Pexidartinib
RxNorm normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
Trial: NCT02296190
Drug: Etripamil
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Trial: NCT00421434
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
Trial: NCT00421434
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
Trial: NCT00421434
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
Trial: NCT02178566
Drug: Inhaled Treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
Trial: NCT02174432
Drug: nalbuphine HCl ER
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nalbuphine HCl ER BID for up to 50 weeks
Trial: NCT00992667
Drug: Apocynin nebulization
RxNorm normalized name: Apocynum cannabinum root extract
DrugBank: Apocynin (DB12618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
Trial: NCT00085202
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00085202
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00666705
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 milligrams(mg) every 12 hours Days 6-11
Trial: NCT00666705
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Trial: NCT00666705
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Trial: NCT00666705
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
Trial: NCT00583986
Drug: Levalbuterol HFA MDI with top mounted actuation indicator
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol HFA MDA with top mounted actuation indicator
Trial: NCT00217646
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01690091
Drug: Metformini hydrochloridum (Siofor 1000 tbl, Berlin)
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)
Trial: NCT01190410
Drug: certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
Trial: NCT01190410
Drug: certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
Trial: NCT01833143
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01833143
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04552743
Drug: MGTA-145
RxNorm normalized name: ALLOGENEIC UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC STEM AND PROGENITOR CELLS MGTA-456
DrugBank: Spanlecortemlocel (DB17130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
Trial: NCT04552743
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
Trial: NCT01862263
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Orally active and highly selective inhibitor of DPP-4
Trial: NCT01862263
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long- acting human insulin analog indicated to improve glycemic control